These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29574794)

  • 1. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.
    Sharma AN; Tan M; Amsterdam EA; Singh GD
    Clin Cardiol; 2018 Mar; 41(3):419-425. PubMed ID: 29574794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report.
    Wang JY; Hu YM; Liu JX; Luo XJ
    J Med Case Rep; 2019 Apr; 13(1):106. PubMed ID: 31018862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options.
    Goldberg MD; Vadera N; Yandrapalli S; Frishman WH
    Cardiol Rev; 2018; 26(6):307-311. PubMed ID: 29794808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Treat Endocrinol; 2004; 3(5):309-18. PubMed ID: 15330678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acromegalic Cardiomyopathy: An Entity on its own? The Effects of GH and IGF-I Excess and Treatment on Cardiovascular Risk Factors.
    Wolf P; Maione L; Kamenický P; Chanson P
    Arch Med Res; 2023 Dec; 54(8):102921. PubMed ID: 38040526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acromegalic cardiomyopathy: a neglected cause of cardiomyopathy.
    Bonora T; Rigamonti E; Capoferri M; De Perna ML
    Clin Ter; 2022 Feb; 173(1):31-34. PubMed ID: 35147643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy.
    Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A
    J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acromegaly and Heart Failure.
    Colao A; Grasso LFS; Di Somma C; Pivonello R
    Heart Fail Clin; 2019 Jul; 15(3):399-408. PubMed ID: 31079698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular complications in acromegaly.
    Vitale G; Pivonello R; Lombardi G; Colao A
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heart failure as a manifestation of acromegaly].
    Ságová I; Dragula M; Kantárová D; Vaňuga A; Vaňuga P
    Vnitr Lek; 2020; 66(4):82-86. PubMed ID: 32972190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment.
    García-Álvarez M; Climent V
    Minerva Endocrinol; 2019 Jun; 44(2):159-168. PubMed ID: 30482010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac effect of thyrotoxicosis in acromegaly.
    Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy.
    Sue M; Yoshihara A; Okubo Y; Ishikawa M; Ando Y; Hiroi N; Shibuya K; Yoshino G
    Intern Med; 2010; 49(19):2117-21. PubMed ID: 20930439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acromegaly and the cardiovascular system.
    Lombardi G; Galdiero M; Auriemma RS; Pivonello R; Colao A
    Neuroendocrinology; 2006; 83(3-4):211-7. PubMed ID: 17047385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Disease in Acromegaly.
    Sharma MD; Nguyen AV; Brown S; Robbins RJ
    Methodist Debakey Cardiovasc J; 2017; 13(2):64-67. PubMed ID: 28740584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acromegalic cardiomyopathy: a review of the literature.
    Matta MP; Caron P
    Pituitary; 2003; 6(4):203-7. PubMed ID: 15237931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.